Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 1c,Condition 2,Condition 3 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,9,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67708,control condition,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001168,ACI.FHH-(D3Wox2-D3Rat59)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,13,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67709,control condition,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001164,ACI.FHH-(D1Rat298-D1Rat90)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,14,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67710,control condition,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001167,ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,14,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67711,control condition,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,11,%,1.0,3.4641,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (50-150 mg/l) ,67712,NG-nitroarginine methyl ester (50-150 mg/l) ,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001168,ACI.FHH-(D3Wox2-D3Rat59)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,18,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (50-150 mg/l) ,67714,NG-nitroarginine methyl ester (50-150 mg/l) ,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001164,ACI.FHH-(D1Rat298-D1Rat90)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,23,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (50-150 mg/l) ,67715,NG-nitroarginine methyl ester (50-150 mg/l) ,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001167,ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,31,%,6.0,20.7846,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (50-150 mg/l) ,67716,NG-nitroarginine methyl ester (50-150 mg/l) ,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,15,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy,67717,right nephrectomy,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001168,ACI.FHH-(D3Wox2-D3Rat59)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,20,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy,67718,right nephrectomy,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001164,ACI.FHH-(D1Rat298-D1Rat90)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,23,%,3.0,10.3923,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy,67719,right nephrectomy,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001167,ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,27,%,3.0,10.3923,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy,67720,right nephrectomy,,,, 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,15,%,1.0,3.4641,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) ,67722,right nephrectomy,,,NG-nitroarginine methyl ester (50-150 mg/l) , 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001168,ACI.FHH-(D3Wox2-D3Rat59)/Eur,male,175 days to 168 days,11,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,39,%,5.0,16.5831,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) ,67723,right nephrectomy,,,NG-nitroarginine methyl ester (50-150 mg/l) , 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001164,ACI.FHH-(D1Rat298-D1Rat90)/Eur,male,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,37,%,4.0,13.8564,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) ,67724,right nephrectomy,,,NG-nitroarginine methyl ester (50-150 mg/l) , 62,"Van Dijk SJ, et al., Kidney Int. 2006",kidney glomerulus integrity trait,,RS:0001167,ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur,male,175 days to 168 days,5,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,64,%,11.0,24.5967,MMO:0000111,ex vivo light microscopy,,0.0,,,,,right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) ,67725,right nephrectomy,,,NG-nitroarginine methyl ester (50-150 mg/l) , 321,"Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9.",pancreas integrity trait,,RS:0000976,WBN/KobSlc,male,90 days,13,,CMO:0001213,percentage of study population developing chronic pancreatitis during a period of time,,,,69,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled protein content diet,67772,controlled protein content diet,,,, 321,"Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9.",pancreas integrity trait,,RS:0000133,BN/CrlCrlj,male,90 days,5,,CMO:0001213,percentage of study population developing chronic pancreatitis during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled protein content diet,67773,controlled protein content diet,,,, 321,"Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9.",pancreas integrity trait,,RS:0000976,WBN/KobSlc,male,120 days,5,,CMO:0001213,percentage of study population developing chronic pancreatitis during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled protein content diet,67774,controlled protein content diet,,,, 321,"Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9.",pancreas integrity trait,,RS:0000976,WBN/KobSlc,male,150 days,5,,CMO:0001213,percentage of study population developing chronic pancreatitis during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled protein content diet,67775,controlled protein content diet,,,, 321,"Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9.",pancreas integrity trait,,RS:0000133,BN/CrlCrlj,male,120 days,5,,CMO:0001213,percentage of study population developing chronic pancreatitis during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled protein content diet,67776,controlled protein content diet,,,, 321,"Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9.",pancreas integrity trait,,RS:0000133,BN/CrlCrlj,male,150 days,6,,CMO:0001213,percentage of study population developing chronic pancreatitis during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled protein content diet,67777,controlled protein content diet,,,, 325,"Schulz A, et al., J Am Soc Nephrol 2003 Dec;14(12):3081-9.",kidney glomerulus quantity,,RS:0000595,MWF/Fub,male,126 days,8,,CMO:0001001,count of superficial glomeruli directly contacting the kidney surface,,,,2.9,,0.5657,1.6,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67833,control condition,,,, 325,"Schulz A, et al., J Am Soc Nephrol 2003 Dec;14(12):3081-9.",kidney glomerulus quantity,,RS:0000743,SHR/Fub,male,126 days,8,,CMO:0001001,count of superficial glomeruli directly contacting the kidney surface,,,,0,,0.0,0.0,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67834,control condition,,,, 325,"Schulz A, et al., J Am Soc Nephrol 2003 Dec;14(12):3081-9.",kidney glomerulus quantity,,RS:0000595,MWF/Fub,male,126 days,8,,CMO:0001002,count of superficial glomeruli not directly contacting the kidney surface,,,,19.4,,1.4142,4.0,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67827,control condition,,,, 325,"Schulz A, et al., J Am Soc Nephrol 2003 Dec;14(12):3081-9.",kidney glomerulus quantity,,RS:0000743,SHR/Fub,male,126 days,8,,CMO:0001002,count of superficial glomeruli not directly contacting the kidney surface,,,,0.1,,0.1061,0.3,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67831,control condition,,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000770,SHRSP/Izm,male,98 days,12,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 14 days),65291,controlled sodium content drinking water (1 %) (for 14 days),,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000770,SHRSP/Izm,female,98 days,10,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 14 days),65292,controlled sodium content drinking water (1 %) (for 14 days),,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000770,SHRSP/Izm,male,112 days,12,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 28 days),65294,controlled sodium content drinking water (1 %) (for 28 days),,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000770,SHRSP/Izm,female,112 days,10,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,60,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 28 days),65295,controlled sodium content drinking water (1 %) (for 28 days),,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000772,SHRSP.WKY-(Klk1-D1Rat116)/Izm,male,98 days,13,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 14 days),65297,controlled sodium content drinking water (1 %) (for 14 days),,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000772,SHRSP.WKY-(Klk1-D1Rat116)/Izm,female,98 days,9,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 14 days),65299,controlled sodium content drinking water (1 %) (for 14 days),,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000772,SHRSP.WKY-(Klk1-D1Rat116)/Izm,male,112 days,13,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 28 days),65300,controlled sodium content drinking water (1 %) (for 28 days),,,, 115,"Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7.",cerebrovascular system integrity trait,,RS:0000772,SHRSP.WKY-(Klk1-D1Rat116)/Izm,male,112 days,9,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,MA:0000168,0,,,,,controlled sodium content drinking water (1 %) (for 28 days),65301,controlled sodium content drinking water (1 %) (for 28 days),,,, 151,"Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.",kidney glomerulus size trait,,RS:0000145,BN/NHsdMcwi,female,101 days to 97 days,22,,CMO:0001166,kidney glomerulus diameter,,,,95,um,1.2,5.6285,MMO:0000111,ex vivo light microscopy,,0.0,plasma creatinine analysis,,,,controlled sodium content diet (0.4 %) (for 35 days),67285,controlled sodium content diet (0.4 %) (for 35 days),,,, 151,"Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.",kidney glomerulus size trait,,RS:0000811,SS/JrHsdMcwi,female,101 days to 97 days,16,,CMO:0001166,kidney glomerulus diameter,,glomerular diameter,,117,um,3.8,15.2,MMO:0000111,ex vivo light microscopy,,0.0,plasma creatinine analysis,,,,controlled sodium content diet (0.4 %) (for 35 days),67286,controlled sodium content diet (0.4 %) (for 35 days),,,, 283,"Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2.",coronary artery integrity trait,,RS:0002214,SS.SR-(D3Arb14-D3Mco36)(D7Mco19-D7Mco7)/Mco,male,118 days to 114 days,6,,CMO:0002303,artery wall thickness to artery total diameter ratio,,,,57.3,%,3.9,9.553,MMO:0000111,ex vivo light microscopy,,0,,,,,controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days),65736,controlled sodium content diet (0.3 %) (between 10 and 12 days),,,controlled sodium content diet (2 %) (for 28 days),controlled sodium content diet (4 %) (between 46 and 48 days) 283,"Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2.",coronary artery integrity trait,,RS:0002213,SS.SR-(D3Arb14-D3Mco36)/Mco,male,118 days to 114 days,6,,CMO:0002303,artery wall thickness to artery total diameter ratio,,,,55,%,3.4,8.3283,MMO:0000111,ex vivo light microscopy,,0,,,,,controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days),65735,controlled sodium content diet (0.3 %) (between 10 and 12 days),,,controlled sodium content diet (2 %) (for 28 days),controlled sodium content diet (4 %) (between 46 and 48 days) 283,"Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2.",coronary artery integrity trait,,RS:0002208,SS.SR-(D7Mco19-D7Mco7)/Jr,male,118 days to 114 days,3,,CMO:0002303,artery wall thickness to artery total diameter ratio,,,,53.3,%,1.9,3.2909,MMO:0000111,ex vivo light microscopy,,0,,,,,controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days),65737,controlled sodium content diet (0.3 %) (between 10 and 12 days),,,controlled sodium content diet (2 %) (for 28 days),controlled sodium content diet (4 %) (between 46 and 48 days) 283,"Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2.",coronary artery integrity trait,,RS:0000817,SS/Jr,male,118 days to 114 days,3,,CMO:0002303,artery wall thickness to artery total diameter ratio,,,,54,%,7.0,12.1244,MMO:0000111,ex vivo light microscopy,,0,,,,,controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days),65738,controlled sodium content diet (0.3 %) (between 10 and 12 days),,,controlled sodium content diet (2 %) (for 28 days),controlled sodium content diet (4 %) (between 46 and 48 days) 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0000943,percentage of study population developing ventral prostate tumorous lesions during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,65824,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0000943,percentage of study population developing ventral prostate tumorous lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,65825,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0000884,prostate tumorous lesion number,,,,5.3,,,,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,65822,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0000884,prostate tumorous lesion number,,,,1.5,,,,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,65823,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",testis integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0001261,percentage of study population developing testis tumors during a period of time,,testis tumor incidence,,92,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,65840,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",testis integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0001261,percentage of study population developing testis tumors during a period of time,,testis tumor incidence,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,65841,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",testis integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0001264,percentage of study population developing bilateral testis tumors during a period of time,,bilateral testis tumor incidence,,25,%,,,MMO:0000111,ex vivo light microscopy,,0.0,necropsy,,,,control condition,67948,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",testis integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0001264,percentage of study population developing bilateral testis tumors during a period of time,,bilateral testis tumor incidence,,88,%,,,MMO:0000111,ex vivo light microscopy,,0.0,necropsy,,,,control condition,67949,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",leukocyte integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0001267,percentage of study population developing leukemia during a period of time,,leukemia incidence,,25,%,,,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,66142,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",leukocyte integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0001267,percentage of study population developing leukemia during a period of time,,leukemia incidence,,0,%,,,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,66143,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0003687,percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of time,,,,92,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109885,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0003687,percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of time,,,,25,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109886,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0003693,number of ventral prostate tumorous lesions with solid structure,,,,3,,0.7506,2.6,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109887,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0003693,number of ventral prostate tumorous lesions with solid structure,,,,0.4,,0.2475,0.7,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109888,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0003688,"percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of time",,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109957,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0003688,"percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of time",,,,38,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109958,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000032,ACI/SegHsd,male,900 days,12,,CMO:0003694,"number of ventral prostate tumorous lesions with round, irregular size nuclei",,,,5.1,,0.6928,2.4,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109959,control condition,,,, 341,"Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6.",prostate integrity trait,,RS:0000312,F344/Jcl,male,900 days,8,,CMO:0003694,"number of ventral prostate tumorous lesions with round, irregular size nuclei",,,,1.3,,0.6364,1.8,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,109960,control condition,,,, 769,"Schulz A, et al., J Am Soc Nephrol 2002 Nov;13(11):2706-14.",kidney glomerulus quantity,,RS:0000596,MWF/FubRkb,not specified,126 days,8,,CMO:0001001,count of superficial glomeruli directly contacting the kidney surface,,,,2.9,,0.5657,1.6,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67601,control condition,,,, 769,"Schulz A, et al., J Am Soc Nephrol 2002 Nov;13(11):2706-14.",kidney glomerulus quantity,,RS:0000529,LEW/Rkb,not specified,126 days,8,,CMO:0001001,count of superficial glomeruli directly contacting the kidney surface,,,,0,,0.0,0.0,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67602,control condition,,,, 769,"Schulz A, et al., J Am Soc Nephrol 2002 Nov;13(11):2706-14.",kidney glomerulus quantity,,RS:0000596,MWF/FubRkb,not specified,126 days,8,,CMO:0001002,count of superficial glomeruli not directly contacting the kidney surface,,,,19.4,,1.4142,4.0,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67599,control condition,,,, 769,"Schulz A, et al., J Am Soc Nephrol 2002 Nov;13(11):2706-14.",kidney glomerulus quantity,,RS:0000529,LEW/Rkb,not specified,126 days,8,,CMO:0001002,count of superficial glomeruli not directly contacting the kidney surface,,,,6.3,,1.096,3.1,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,67600,control condition,,,, 567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",brain integrity trait,,RS:0001433,SHRSP.WKY-(D1Wox29-D1Arb21)/Izm,male,153 days,15,,CMO:0001013,brain infarction volume,,,,66.4,mm3,5.5513,21.5,MMO:0000111,ex vivo light microscopy,,0,,MCA occlusion,3,days,control condition (for 153 days),65950,control condition (for 153 days),,,, 567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",brain integrity trait,,RS:0000770,SHRSP/Izm,male,153 days,17,,CMO:0001013,brain infarction volume,,,,103.4,mm3,6.0149,24.8,MMO:0000111,ex vivo light microscopy,,0,,MCA occlusion,3,days,control condition (for 153 days),65951,control condition (for 153 days),,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000016,ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur,male,180 days to 173 days,7,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,2,%,1.0,2.6458,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,67951,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000020,ACI.FHH-(D1Rat324-D1Rat156)/Eur,male,180 days to 173 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,15,%,3.0,8.4853,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,67952,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,180 days to 173 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,8,%,2.0,5.6569,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,67950,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,, 709,"Lella V, et al., Int J Cancer. 2007 Oct 15;121(8):1738-43.",mammary gland development trait,,RS:0001449,SPRD/Ztm,female,55 days,5,,CMO:0001084,mammary gland terminal end bud count,,,,84.6,,12.4,27.7272,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,66135,control condition,,,, 709,"Lella V, et al., Int J Cancer. 2007 Oct 15;121(8):1738-43.",mammary gland development trait,,RS:0001452,SPRD.WKY-(D5Rat190-D5Rat114)/Ibmm,female,55 days,5,,CMO:0001084,mammary gland terminal end bud count,,,,59.3,,2.6,5.8138,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,66136,control condition,,,, 709,"Lella V, et al., Int J Cancer. 2007 Oct 15;121(8):1738-43.",mammary gland development trait,,RS:0001450,SPRD.WKY-(D18Wox8-D18Rat44)/Ibmm,female,55 days,5,,CMO:0001084,mammary gland terminal end bud count,,,,60.3,,4.9,10.9567,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,66137,control condition,,,, 709,"Lella V, et al., Int J Cancer. 2007 Oct 15;121(8):1738-43.",mammary gland development trait,,RS:0001070,WKY/Ztm,female,55 days,5,,CMO:0001084,mammary gland terminal end bud count,,,,33.8,,2.1,4.6957,MMO:0000111,ex vivo light microscopy,,0,,,,,control condition,66138,control condition,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,15,%,3.0,10.3923,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy,68874,unilateral nephrectomy,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001165,ACI.FHH-(D1Rat384-D1Rat156)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,13,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy,68875,unilateral nephrectomy,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001162,ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,30,%,3.0,10.3923,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy,68876,unilateral nephrectomy,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001166,ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,12,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy,68877,unilateral nephrectomy,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,8,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,68878,control condition,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001165,ACI.FHH-(D1Rat384-D1Rat156)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,14,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,68879,control condition,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001162,ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,21,%,2.0,6.9282,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,68880,control condition,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001166,ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,8,%,1.0,3.4641,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,68881,control condition,,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,20,%,3.0,10.3923,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days),68882,unilateral nephrectomy,,,NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days), 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001165,ACI.FHH-(D1Rat384-D1Rat156)/Eur,not specified,175 days to 168 days,11,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,42,%,6.0,19.8997,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days),68883,unilateral nephrectomy,,,NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days), 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001166,ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur,not specified,175 days to 168 days,9,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,29,%,4.0,12.0,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days),68885,unilateral nephrectomy,,,NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days), 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,11,%,1.0,3.4641,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),68886,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001165,ACI.FHH-(D1Rat384-D1Rat156)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,20,%,3.0,10.3923,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),68887,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001162,ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,33,%,3.0,10.3923,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),68888,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),,,, 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001162,ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur,not specified,175 days to 168 days,2,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,59,%,11.0,15.5563,MMO:0000111,ex vivo light microscopy,,0.0,,unilateral nephrectomy,126,days,unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days),68884,unilateral nephrectomy,,,NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days), 832,"van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12.",kidney glomerulus integrity trait,,RS:0001166,ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur,not specified,175 days to 168 days,12,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,"Original CMO_ID, CMO:0001176, was merged into current ID and field automatically updated. 4-26-2013",,14,%,7.0,24.2487,MMO:0000111,ex vivo light microscopy,,0.0,,,,,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),68889,NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days),,,, 870,"Kota LT, et al., Physiol Genomics. 2008 Jun 3;.",kidney integrity trait,,RS:0000565,LOU/Ins,male,126 days,20,,CMO:0001203,percentage of study population developing hematuria during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,68637,control condition,,,, 870,"Kota LT, et al., Physiol Genomics. 2008 Jun 3;.",kidney integrity trait,,RS:0000152,BN/Rj,male,126 days,60,,CMO:0001203,percentage of study population developing hematuria during a period of time,,,,16.7,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,68638,control condition,,,, 1076,"Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33.",sperm quantity,,RS:0000715,SHR/OlaIpcv,male,90 days,9,,CMO:0000638,motile sperm count to total sperm count ratio,,,,57,%,1.5667,4.7,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,69015,control condition,,,, 1076,"Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33.",sperm quantity,,RS:0000116,BN-Lx/Cub,male,90 days,9,,CMO:0000638,motile sperm count to total sperm count ratio,,,,67,%,0.8667,2.6,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,69016,control condition,,,, 1076,"Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33.",sperm quantity,,RS:0000715,SHR/OlaIpcv,male,90 days,9,,CMO:0000644,normal sperm count to total sperm count ratio,,normal sperm to total sperm ratio,,80.2,%,0.4333,1.3,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,69021,control condition,,,, 1076,"Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33.",sperm quantity,,RS:0000116,BN-Lx/Cub,male,90 days,9,,CMO:0000644,normal sperm count to total sperm count ratio,,normal sperm to total sperm ratio,,84.8,%,0.8,2.4,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,69022,control condition,,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0000505,LEW.BN-(D10Rat43-D10Mco4)/Rj,both,174 days to 98 days,4,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75681,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001356,LEW.BN-(D10Mco17-D10Mco14)/Ciml,both,174 days to 98 days,3,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75682,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001358,LEW.BN-(D10Mco17-D10Rat221)/Ciml,both,174 days to 98 days,3,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,66.67,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75683,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001355,LEW.BN-(D10Arb4-D10Rat133)/Ciml,both,174 days to 98 days,4,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,75,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75684,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001359,LEW.BN-(D10Mgh7-D10Rat221)/Ciml,both,174 days to 98 days,4,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75685,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001360,LEW.BN-(D10Rat32-D10Rat133)/Ciml,both,174 days to 98 days,4,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,75,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75686,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001357,LEW.BN-(D10Mco17-D10Rat133)/Ciml,both,174 days to 98 days,3,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75687,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0000122,BN.LEW-(D10Rat32-D10Mgh4)/Rj,both,174 days to 98 days,5,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75688,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001202,BN.LEW-(D10Mco17-D10Mco14)/Ciml,both,174 days to 98 days,5,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,40,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75689,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0001201,BN.LEW-(D10Mco17-D10Rat80)/Ciml,both,174 days to 98 days,5,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75690,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1518,"Cavailles P, et al., Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.",brain integrity trait,,RS:0003637,BN.LEW-(D10Rat32-D10Rat133)/Ciml,both,174 days to 98 days,5,,CMO:0002028,percentage of study population displaying Toxoplasma gondii brain cysts at a point in time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,Toxoplasma gondii cysts (20 null) (for 42 days),75691,Toxoplasma gondii cysts (20 null) (for 42 days),,,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001622,percentage of study population developing pituitary gland hyperplastic lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69908,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001622,percentage of study population developing pituitary gland hyperplastic lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69912,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001622,percentage of study population developing pituitary gland hyperplastic lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69916,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001618,percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69909,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001618,percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69913,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001618,percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time,,,,67,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69917,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001617,percentage of study population developing pituitary tumors that replace the entire gland during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69910,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001617,percentage of study population developing pituitary tumors that replace the entire gland during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69914,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001617,percentage of study population developing pituitary tumors that replace the entire gland during a period of time,,,,33,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69918,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001619,percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69911,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001619,percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69915,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001619,percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time,,,,67,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69919,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001757,lactotroph count to total pituicyte count ratio in prolactinoma,,lactotroph to total pituicyte ratio,,86,%,9.0,22.0454,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69920,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0001590,WF/CrCrli,not specified,0 days,20,,CMO:0001803,percentage of study population developing benign colorectal tumors during a period of time,,,,25,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70375,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0000032,ACI/SegHsd,not specified,0 days,20,,CMO:0001803,percentage of study population developing benign colorectal tumors during a period of time,,,,75,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70376,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0001590,WF/CrCrli,not specified,0 days,20,,CMO:0001795,benign colorectal tumor number,,,,0.25,,0.1386,0.62,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70377,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0000032,ACI/SegHsd,not specified,0 days,20,,CMO:0001795,benign colorectal tumor number,,,,1.5,,0.313,1.4,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70378,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0001590,WF/CrCrli,not specified,0 days,20,,CMO:0002076,poorly differentiated malignant colorectal tumor number,,,,1.08,,0.0648,0.29,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70385,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0001590,WF/CrCrli,not specified,0 days,20,,CMO:0002076,poorly differentiated malignant colorectal tumor number,,,,0.21,,0.0492,0.22,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70386,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0001590,WF/CrCrli,not specified,0 days,20,,CMO:0002071,percentage of study population developing poorly differentiated malignant colorectal tumors during a period of time,,,,80,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70383,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0000032,ACI/SegHsd,not specified,0 days,20,,CMO:0002071,percentage of study population developing poorly differentiated malignant colorectal tumors during a period of time,,,,15,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70384,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0000032,ACI/SegHsd,not specified,0 days,20,,CMO:0002075,well differentiated malignant colorectal tumor number,,,,0.28,,0.0358,0.16,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70381,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0001590,WF/CrCrli,not specified,0 days,20,,CMO:0002075,well differentiated malignant colorectal tumor number,,,,0.16,,0.0425,0.19,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70382,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0001590,WF/CrCrli,not specified,0 days,20,,CMO:0002072,percentage of study population developing well differentiated malignant colorectal tumors during a period of time,,,,15,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70379,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1378,"De Miglio MR, et al., Carcinogenesis. 2007 May 17;.",colorectal integrity trait,,RS:0000032,ACI/SegHsd,not specified,0 days,20,,CMO:0002072,percentage of study population developing well differentiated malignant colorectal tumors during a period of time,,,,20,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",70380,"1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)",,,, 1128,"Shiozawa M, et al., J Am Soc Nephrol 2000 Nov;11(11):2068-78.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,98 days to 91 days,21,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,3.2,%,0.3928,1.8,MMO:0000111,ex vivo light microscopy,,0.0,performed at 5 to 6 weeks of age,unilateral nephrectomy,39,days,unilateral nephrectomy,69158,unilateral nephrectomy,,,, 1128,"Shiozawa M, et al., J Am Soc Nephrol 2000 Nov;11(11):2068-78.",kidney glomerulus integrity trait,,RS:0000018,FHH/Eur,male,98 days to 91 days,26,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,52.1,%,2.2946,11.7,MMO:0000111,ex vivo light microscopy,,0.0,performed at 5 to 6 weeks of age,unilateral nephrectomy,39,days,unilateral nephrectomy,69159,unilateral nephrectomy,,,, 1125,"Rubattu S, et al., Nat Genet 1996 Aug;13(4):429-34",cerebrovascular system integrity trait,,RS:0001444,SHRSP/Bbb,both,84 days,30,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (for 42 days) and controlled sodium content drinking water (1 %) (for 42 days) and controlled potassium content diet (6.3 mg/g) (for 42 days),69117,controlled sodium content diet (3.7 mg/g) (for 42 days),controlled sodium content drinking water (1 %) (for 42 days),controlled potassium content diet (6.3 mg/g) (for 42 days),, 1125,"Rubattu S, et al., Nat Genet 1996 Aug;13(4):429-34",cerebrovascular system integrity trait,,RS:0003421,SHR/Bbb,both,182 days,30,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,20,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (for 140 days) and controlled sodium content drinking water (1 %) (for 140 days) and controlled potassium content diet (6.3 mg/g) (for 140 days),69118,controlled sodium content diet (3.7 mg/g) (for 140 days),controlled sodium content drinking water (1 %) (for 140 days),controlled potassium content diet (6.3 mg/g) (for 140 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0001444,SHRSP/Bbb,not specified,88 days to 70 days,31,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (between 70 and 88 days) and controlled sodium content drinking water (1 %) (between 70 and 88 days) and controlled potassium content diet (6.3 mg/g) (between 70 and 88 days),69119,controlled sodium content diet (3.7 mg/g) (between 70 and 88 days),controlled sodium content drinking water (1 %) (between 70 and 88 days),controlled potassium content diet (6.3 mg/g) (between 70 and 88 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0002192,SHRSR/Bbb,not specified,126 days,18,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (for 84 days) and controlled sodium content drinking water (1 %) (for 84 days) and controlled potassium content diet (6.3 mg/g) (for 84 days),69120,controlled sodium content diet (3.7 mg/g) (for 84 days),controlled sodium content drinking water (1 %) (for 84 days),controlled potassium content diet (6.3 mg/g) (for 84 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0002535,SHRSP.SHRSR-(Klk1-Mt1-ps1)/Bbb,not specified,91 days to 70 days,20,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,61,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (between 28 and 49 days) and controlled sodium content drinking water (1 %) (between 28 and 49 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 49 days),69121,controlled sodium content diet (3.7 mg/g) (between 28 and 49 days),controlled sodium content drinking water (1 %) (between 28 and 49 days),controlled potassium content diet (6.3 mg/g) (between 28 and 49 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0002537,SHRSP.SHRSR-(D1Rat134-Mt1-ps1)/Bbb,not specified,91 days to 70 days,34,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,63,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (between 28 and 49 days) and controlled sodium content drinking water (1 %) (between 28 and 49 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 49 days),69122,controlled sodium content diet (3.7 mg/g) (between 28 and 49 days),controlled sodium content drinking water (1 %) (between 28 and 49 days),controlled potassium content diet (6.3 mg/g) (between 28 and 49 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0002195,SHRSR.SHRSP-(Klk1-Mt1-ps1)/Bbb,not specified,133 days to 81 days,33,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,20,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (between 42 and 91 days) and controlled sodium content drinking water (1 %) (between 42 and 91 days) and controlled potassium content diet (6.3 mg/g) (between 42 and 91 days),69123,controlled sodium content diet (3.7 mg/g) (between 42 and 91 days),controlled sodium content drinking water (1 %) (between 42 and 91 days),controlled potassium content diet (6.3 mg/g) (between 42 and 91 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0002193,SHRSR.SHRSP-(D1Rat134-Mt1-ps1)/Bbb,not specified,133 days to 81 days,31,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,20,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (between 42 and 91 days) and controlled sodium content drinking water (1 %) (between 42 and 91 days) and controlled potassium content diet (6.3 mg/g) (between 42 and 91 days),69124,controlled sodium content diet (3.7 mg/g) (between 42 and 91 days),controlled sodium content drinking water (1 %) (between 42 and 91 days),controlled potassium content diet (6.3 mg/g) (between 42 and 91 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0002535,SHRSP.SHRSR-(Klk1-Mt1-ps1)/Bbb,not specified,109 days to 70 days,33,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (between 28 and 67 days) and controlled sodium content drinking water (1 %) (between 28 and 67 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 67 days),84575,controlled sodium content diet (3.7 mg/g) (between 28 and 67 days),controlled sodium content drinking water (1 %) (between 28 and 67 days),controlled potassium content diet (6.3 mg/g) (between 28 and 67 days),, 1126,"Rubattu S, et al., Physiol Genomics. 2006 Oct 11;27(2):108-13. Epub 2006 Jul 11.",cerebrovascular system integrity trait,,RS:0002537,SHRSP.SHRSR-(D1Rat134-Mt1-ps1)/Bbb,not specified,133 days to 70 days,35,,CMO:0000932,percentage of study population developing cerebrovascular lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,controlled sodium content diet (3.7 mg/g) (between 28 and 91 days) and controlled sodium content drinking water (1 %) (between 28 and 91 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 91 days),84576,controlled sodium content diet (3.7 mg/g) (between 28 and 91 days),controlled sodium content drinking water (1 %) (between 28 and 91 days),controlled potassium content diet (6.3 mg/g) (between 28 and 91 days),, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0000152,BN/Rj,male,126 days to 120 days,7,,CMO:0002562,number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteries,,number of internal elastic lamina ruptures,,59.4,,3.6663,9.7,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96767,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0000152,BN/Rj,female,126 days to 120 days,3,,CMO:0002562,number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteries,,number of internal elastic lamina ruptures,,36.3,,10.3923,18.0,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96768,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0003786,LOU/MBbb,female,126 days to 120 days,3,,CMO:0002562,number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteries,,number of internal elastic lamina ruptures,,0,,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,97049,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0003786,LOU/MBbb,male,126 days to 120 days,8,,CMO:0002562,number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteries,,number of internal elastic lamina ruptures,,0,,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,97048,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",renal artery integrity trait,,RS:0000152,BN/Rj,male,126 days to 120 days,7,,CMO:0002563,number of ruptures of the internal elastic lamina of the renal arteries,,number of internal elastic lamina ruptures,,2.14,,0.5518,1.46,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96771,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",renal artery integrity trait,,RS:0003786,LOU/MBbb,male,126 days to 120 days,8,,CMO:0002563,number of ruptures of the internal elastic lamina of the renal arteries,,number of internal elastic lamina ruptures,,0.13,,0.1237,0.35,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96777,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",renal artery integrity trait,,RS:0000152,BN/Rj,female,126 days to 120 days,3,,CMO:0002563,number of ruptures of the internal elastic lamina of the renal arteries,,number of internal elastic lamina ruptures,,0.33,,0.3349,0.58,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96772,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",renal artery integrity trait,,RS:0003786,LOU/MBbb,female,126 days to 120 days,8,,CMO:0002563,number of ruptures of the internal elastic lamina of the renal arteries,,number of internal elastic lamina ruptures,,0,,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,97047,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0000152,BN/Rj,male,126 days to 120 days,7,,CMO:0002564,arterial internal elastic lamina rupture composite score,,internal elastic lamina rupture score,,118.7,,7.1435,18.9,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96769,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0000152,BN/Rj,female,126 days to 120 days,3,,CMO:0002564,arterial internal elastic lamina rupture composite score,,internal elastic lamina rupture score,,65,,21.8238,37.8,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96770,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0003786,LOU/MBbb,female,126 days to 120 days,3,,CMO:0002564,arterial internal elastic lamina rupture composite score,,internal elastic lamina rupture score,,0,,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,97051,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0003786,LOU/MBbb,male,126 days to 120 days,8,,CMO:0002564,arterial internal elastic lamina rupture composite score,,internal elastic lamina rupture score,,0,,,,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,97050,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0003786,LOU/MBbb,female,126 days to 120 days,10,,CMO:0002566,patent ductus arteriosus score,,score of PDA,,0.17,,0.1708,0.54,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96776,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0000152,BN/Rj,male,126 days to 120 days,61,,CMO:0002566,patent ductus arteriosus score,,score of PDA,,3.78,,0.3662,2.86,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96773,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0000152,BN/Rj,female,126 days to 120 days,3,,CMO:0002566,patent ductus arteriosus score,,score of PDA,,4,,1.478,2.56,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96774,control condition,,,, 1680,"Kota L, et al., Physiol Genomics. 2007 Jun 19;30(1):17-25. Epub 2007 Mar 13.",artery integrity trait,,RS:0003786,LOU/MBbb,male,126 days to 120 days,27,,CMO:0002566,patent ductus arteriosus score,,score of PDA,,0.28,,0.1309,0.68,MMO:0000111,ex vivo light microscopy,,0.0,,,,,control condition,96775,control condition,,,,